DOI: http://dx.doi.org/10.18203/2349-2902.isj20214098

A study of association between serum thyroid stimulating hormone concentration and thyroid cancer and also to assess whether serum thyroid stimulating hormone levels are of value in predicting malignancy in patients with thyroid swelling

Benny Bright, Joe Mathew, Jacob P. Thomas, Robinson George

Abstract


Background: Thyroid neoplasm includes both benign and malignant tumors arising in the thyroid gland. Although thyroid cancer accounts for less than 1% of all cancers, the challenge to clinicians is to identify the minority of thyroid nodules that harbor malignancy. There are a number of well-established predictors of malignancy in thyroid nodules. More recently a few studies have suggested that higher concentration of thyroid stimulating hormone (TSH), even within the normal range are associated with subsequent diagnosis of thyroid cancer in patients with thyroid nodules and even higher serum TSH levels have been found associated with advanced stages of thyroid cancer. 

Methods: A prospective study was conducted on 220 cases without overt thyroid dysfunction attending Department of general surgery, Pushpagiri institute of medical science, Thiruvalla.  

Results: In our study incidence of malignancy of thyroid carcinoma was highest in patients with serum TSH concentrations, in range of 3.5 mIU/l-5.25 mIU/l, 55 patients out of 220 patients. Individually, incidence of papillary carcinoma (PC) (36/55 patients), follicular carcinoma (FC) (17/55 patients) and Hurthle cell carcinoma (HCC) (2/55 patients) were more in patients with higher TSH. So, from the study it can be clearly state that elevated TSH can be used as an independent predictor of thyroid malignancy. Higher TSH values are associated with papillary thyroid carcinoma.

Conclusions: An elevated TSH can be used as an independent predictor of thyroid malignancy, especially for anticipating a probability of papillary carcinoma of thyroid.  


Keywords


TSH, Multinodular goiter, Fine needle aspiration

Full Text:

PDF

References


Harrison BJ, Maddox PR, Smith DM. Disorders of thyroid gland. Cuschieri A, Steele RJC, Moossa AR, Essential Surgical Practice. Arnold, London. 4th edi. 2002;95-110.

Beauchamp, Mattox E. Sabiston’s Text Book of Surgery. 16th Edition. Towns med. 2000’603-28.

William F. Investigations of excess thyroid cancer incidence in los Alanco. Division of epidemiology. 1996;23(7):885-91.

Brunicardi FC, Anderson DK, Timothy RB, David LD, Schwartz S. Principles of Surgery. 6th Edi. Mc grew Hill. 2020;1611-80.

Kim EB, Susan MB, Scott B, Hidden LB. William. F. Ganong. Review of medical physiology. Mc Raw Hill Lange, 22nd edition. 2010;327-8.

Papini E, Petrucci L, Guglielmi R. Long-term changes in nodular goiter A 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab. 1998;83:780-83.

Pujol P, Daures JP, Nsakala N. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab. 1996;81:4318-23.

Jonklaas J. Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. Thyroid. 2008;18:943-52.

Hegedus L. Management of simple nodular goiter: current status and future perspectives. Endocrine Reviews. 2003;24:102-32.

Okayasu I. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans. Cancer. 1995;76:2312-8.

Gharib H. Changing trends in thyroid practice: understanding nodular thyroid disease. Endocrine Practice. 2004;10:31-9.

Vermiglio F. Changes in both size and cytological features of thyroid nodule after levothyroxine treatment. Clin Endocrinol. 2003;59(3):347-53.

Ichikawa Y. Presence of TSH receptor in thyroid neoplasms. J Clin Endocrinol Metab. 1976;42. 395–398

Gudmundsson J, Sulem P, Huiling H, Daniel FG, John GJ. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European population. Nature Genetics. 2009;41:460-64.

Boelaert K, Horacek J, Holder RL, Sheppard MC. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodule investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006;91:295-301.

Boelaert K. The association between serum TSH concentration and thyroid cancer. Endocr Relat Cancer. 2009;16:1065-72.

Haymart MR. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associate with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93:809-14.

Polyzos SA. Serum thyrotropin concentration as biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J Cancer Res Clin Oncol. 2008;134:953-60.

Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F et al. Lower levels of TSH are associated to a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocrine-Related Cancer. 2008;16:1251-60.

Brewer C, Yeager N, Di CA. Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Res. 2007;67:8002-6.